Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract

References

• Qvist P, Christgau S, Pedersen BJ, et al. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 2002; 31: 57–61
   PubMed Web of Science ®Google Scholar
• Schlemmer A, Hassager C, Pedersen BJ, et al. Posture, age, menopause, and osteopenia do not influence the circadian variation in the urinary excretion of pyridinium crosslinks. J Bone Miner Res 1994; 9: 1883–8
   PubMed Web of Science ®Google Scholar
• Schlemmer A, Hassager C. Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption. Eur J Endocrinol 1999; 140: 332–7
   PubMed Web of Science ®Google Scholar
• Heshmati HM, Riggs BL, Burritt MF, et al. Effects of the circadian variation in serum cortisol on markers of bone turnover and calcium homeostasis in normal postmenopausal women. J Clin Endocrinol Metab 1998; 83: 751–6
   PubMed Web of Science ®Google Scholar
• Ledger GA, Burritt MF, Kao PC, O'Fallen WM, Riggs BL, Khosla S. Role of parathyroid hormone in mediating nocturnal and age-related increases in bone resorption. J Clin Endocrinol Metab 1995; 80: 3304–10
   PubMed Web of Science ®Google Scholar
• Henriksen DB, Alexandersen P, Bjarnason NH, Vilsboll T, Hartmann B, Henriksen EE, et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 2003; 18: 2180–9
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Glucagon-like peptide 2. J Clin Endocrinol Metab 2001; 86: 1759–64
   PubMed Web of Science ®Google Scholar
• Holst JJ. Glucagon-like peptide 1 (GLP-1): an intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol Metab 1999; 10: 229–35
   PubMed Web of Science ®Google Scholar
• Yusta B, Huang L, Munroe D, Wolff G, Fantaske R, Sharma S, et al. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology 2000; 119: 744–55
   PubMed Web of Science ®Google Scholar
• Guan X, Karpen HE, Stephens J, Bukowski JT, Niu S, Zhang G, et al. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 2006; 130: 150–64
   PubMed Web of Science ®Google Scholar
• Orskov C, Hartmann B, Poulsen SS, et al. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Reg Pept 2005; 124: 105–12
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 1996; 93: 7911–6
   PubMed Web of Science ®Google Scholar
• Wojdemann M, Wettergren A, Hartmann B, et al. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scand J Gastroenterol 1998; 33: 828–32
   PubMed Web of Science ®Google Scholar
• Wojdemann M, Wettergren A, Hartmann B, Hilsted L, Holst JJ. Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2. J Clin Endocrinol Metab 1999; 84: 2513–7
   PubMed Web of Science ®Google Scholar
• Kouris GJ, Liu Q, Rossi H, Djuriein G, Gattuso P, Nathan C, et al. The effect of glucagon-like peptide 2 on intestinal permeability and bacterial translocation in acute necrotizing pancreatitis. Am J Surg 2001; 181: 571–5
   PubMed Web of Science ®Google Scholar
• Jeppesen PB, Hartmann B, Thulesen J, Graff J, Lohmann J, Hansen BS, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 2001; 120: 806–15
   PubMed Web of Science ®Google Scholar
• Jeppesen PB, Sanguinetti EL, Buchman A, Howard L, Scolapio JS, Ziegler TR, et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 2005; 54: 1224–31
   PubMed Web of Science ®Google Scholar
• Schoon EJ, van Nunen AB, Wouters RS, et al. Osteopenia and osteoporosis in Crohn's disease: prevalence in a Dutch population-based cohort. Scand J Gastroenterol 2000; Suppl 232: 43–7
   Google Scholar
• Haderslev KV, Tjellesen L, Haderslev PH, Staun M. Assessment of the longitudinal changes in bone mineral density in patients receiving home parenteral nutrition. J Parent Ent Nutr 2004; 28: 289–94
   PubMed Web of Science ®Google Scholar
• Jeppesen PB, Hartmann B, Thulesen J, Hansen BS, Holst JJ, Poulsen SS, et al. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut 2000; 47: 370–6
   PubMed Web of Science ®Google Scholar
• Holst JJ, Hartmann B, Gottschalck IB, Jeppesen PB, Miholic J, Henriksen DB. Bone resorption is decreased postprandially by intestinal factors and glucagon-like peptide-2 is a possible candidate. Scand J Gastroenterol 2007; 42: 814–20
   PubMed Web of Science ®Google Scholar
• Haderslev KV, Jeppesen PB, Hartmann B, Thulesen J, Sorensen HA, Graff J, et al. Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon. Scand J Gastroenterol 2002; 37: 392–8
   PubMed Web of Science ®Google Scholar
• Bollag RJ, Zhong Q, Ding KH, Phillips P, Zhong L, Qin F, et al. Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects. Mol Cell Endocrinol 2001; 177: 35–41
   PubMed Web of Science ®Google Scholar
• Xiao Q, Boushey RP, Drucker DJ, Brubaker P. Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans. Gastroenterology 1999; 117: 99–105
   PubMed Web of Science ®Google Scholar
• Hartmann B, Johnsen AH, Orskov C, Adelhorst K, Thim L, Holst JJ, et al. Structure, measurement, and secretion of human glucagon-like peptide-2. Peptides 2000; 21: 73–80
   PubMed Web of Science ®Google Scholar
• Holst JJ, Bersani M. Assays for peptide products of somatostatin gene expression. Academic Press, London 1991; 3–32
   Google Scholar
• Hvidberg A, Nielsen MT, Hilsted J, Ørskov C, Holst. Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. Metabolism 1994; 43: 104–8
   PubMed Web of Science ®Google Scholar
• Meier JJ, Gallwitz B, Askenas M, Vollmer K, Deacon CF, Holst JJ, et al. Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes. Diabetologia 2005; 48: 1872–81
   PubMed Web of Science ®Google Scholar
• Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Qvist P, et al. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 1998; 44: 2281–9
   PubMed Web of Science ®Google Scholar
• Rosenquist C, Qvist P, Bjarnason N, Christiansen C. Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem 1995; 41: 1439–45
   PubMed Web of Science ®Google Scholar
• Haderslev KV, Jeppesen PB, Sorensen HA, Mortensen PB, Staun M. Vitamin D status and measurements of markers of bone metabolism in patients with small intestinal resection. Gut 2003; 52: 653–8
   PubMed Web of Science ®Google Scholar
• Bischoff SC, Herrmann A, Goke M, et al. Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol 1997; 92: 1157–63
   PubMed Web of Science ®Google Scholar
• Bollag RJ, Zhong Q, Phillips P, Min L, Zhong L, Cameron R, et al. Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology 2000; 141: 1228–35
   PubMed Web of Science ®Google Scholar
• Henriksen DB, Alexandersen P, Hartmann B, Adrian CL, Byrjalsen I, Bone HG, et al. Disassociation of bone resorption and formation by GLP-2 A 14-day study in healthy postmenopausal women. Bone 2007; 40: 723–9
   PubMed Web of Science ®Google Scholar
• Haderslev KV, Jeppesen PB, Hartmann B, Thulesen J, Sorensen HA, Graff J, et al. Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon. Scand J Gastroenterol 2002; 37: 392–8
   PubMed Web of Science ®Google Scholar
• Bjerknes M, Cheng H. Modulation of specific intestinal epithelial progenitors by enteric neurons. Proc Natl Acad Sci USA 2001; 98: 12497–502
   PubMed Web of Science ®Google Scholar